Cytosolix logo
Cytosolix logo

Cytosolix

cytosolix.com
cytosolix.com • HQ: Tolland, United States • Venture - Series Unknown 2023 • 11-50 employees • Startup • New
HQ: Tolland, United States • Venture - Series Unknown 2023 • 11-50 employees • Startup • New
Actively hiring
Oncology Therapeutics
Follow
Overview
Salaries
Products
People
Growth
Offices
Financials

Funding and backers

Total raised
$6.6M
1 round on record
Latest round
$6.6M
Venture round · Jun 2023 · 3 yr ago
Team
11-50
employees, estimated range
Backers
1
BlueYard Capital
The money's age
Long since its last round
39 months since the last round · not hiring
Momentum
0/100
no fresh signals
Funding rounds
RoundDateAmountInvestorsSource
Venture round Jun 2023 $6.6M — SEC Form D
Registers and programsofficial lists and records that name the company
Legal entity Cytosolix, Inc. sec
Founders and leadersfrom filings, registers and the company's site
John DeaconExecutive Officer, DirectorSEC Form D
Colin FosterExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
BlueYard Capital fund
Similar startupsby what they do, their industry and backers
TwoStep11-50 employees
TwoStep Therapeutics. Developing tumor-targeted therapies with broad applicability across solid tumors.
AlixiaVenture round $1.8M · 2 yr ago • Founded 2022
Targeting the Tumor Ecosystem to address cancer drug resistance and improve patients’ lives.
Origin
What if we made as many cancer drugs next year as we have in the last decade?
Yemaachi Biotechnology
Yemaachi is creating the world's most diverse cancer bio-database to develop the next generation of cancer drugs that are effective in…
NormunityVenture round $37.5M · 20 mo ago • Founded 2020 • 201-500 employees
We create medicines that free normal immunity to defeat cancer using proprietary platforms that uncover novel immuno-oncology mechanisms.
3T BiosciencesFounded 2017 • 51-200 employees
We are solving a major bottleneck in the field of targeted biotherapeutics in oncology – the identification of novel targets for the…

Overview

Our Tumor Activated Permeability (TAP) Platform produces weakly-acidic derivatives of known oncology drugs that already work. It preserves the drug.

People

John Deacon
Executive Officer, Director
SEC Form D
Colin Foster
Executive Officer, Director
SEC Form D
Jason Whitmire
Director
SEC Form D
Alex Brunicki
Director
SEC Form D
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove

Offices

Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Tolland United States
HQ
10-50 est. staff

Financials

Total raised
$6.6M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
Round Announced Amount
Venture - Series Unknown 2023 $6.6M Details